California Doctor Loses DEA License, Can't Prescribe Controlled Drugs
Published Date: 6/10/2025
Notice
Summary
Dr. Harry Kram from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite being notified, he didn’t ask for a hearing, so the DEA officially revoked his registration by default. This means Dr. Kram can’t legally prescribe or handle controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — Dr. Kram
Dr. Harry Kram (DEA Certificate No. AK1539444) has had his DEA registration revoked effective July 10, 2025. This revocation means he cannot legally prescribe, dispense, or handle controlled substances, which prevents him from providing those aspects of medical care and will affect his medical practice and related income.
Pending DEA Applications Denied in California
The DEA denied any pending applications by Harry Kram, M.D., to renew or modify his registration and denied any pending applications for additional registration in California. That denial accompanies the final order effective July 10, 2025, and prevents him from obtaining DEA registration while he lacks state authority to practice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-10500 — Marine Mammals; File No. 28712
Kaitlin Allen, Ph.D., from Woods Hole Oceanographic Institution, got a permit to import, export, and receive marine mammal parts for science research. This means she can legally handle these parts to study marine mammals better. The permit helps support important research without any extra costs or deadlines mentioned.
Next: 2025-10502 — Serge Menkin, M.D.; Decision and Order
Dr. Serge Menkin from New Jersey lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of January 31, 2025. This means Dr. Menkin can’t legally work with controlled drugs anymore, and the decision is final.